Notwithstanding the continuous progress made in cancer treatment in the last 20 years, and the availability of new targeted therapies, metastatic Breast Cancer (BC) is still incurable. Targeting the cell cycle machinery has emerged as an attractive strategy to tackle cancer progression, showing very promising results in the preclinical and clinical settings. The first selective inhibitors of CDK4/6 received breakthrough status and FDA approval in combination with letrozole (February 2015) and fulvestrant (February 2016) as first-line therapy in ER-positive advanced and metastatic BC. Considering the success of this family of compounds in hormone-positive BC, new possible applications are being investigated in other molecular subtypes. This review summarizes the latest findings on the use of CDK4/6 inhibitors in HER2 positive BC.

CDK4/6 inhibitors in HER2-positive breast cancer / Corona, Silvia Paola; Ravelli, Andrea; Cretella, Daniele; Cappelletti, Maria Rosa; Zanotti, Laura; Dester, Martina; Gobbi, Angela; Petronini, Pier Giorgio; Generali, Daniele. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 112:(2017), pp. 208-214. [10.1016/j.critrevonc.2017.02.022]

CDK4/6 inhibitors in HER2-positive breast cancer

Ravelli, Andrea;Cretella, Daniele;Petronini, Pier Giorgio;
2017-01-01

Abstract

Notwithstanding the continuous progress made in cancer treatment in the last 20 years, and the availability of new targeted therapies, metastatic Breast Cancer (BC) is still incurable. Targeting the cell cycle machinery has emerged as an attractive strategy to tackle cancer progression, showing very promising results in the preclinical and clinical settings. The first selective inhibitors of CDK4/6 received breakthrough status and FDA approval in combination with letrozole (February 2015) and fulvestrant (February 2016) as first-line therapy in ER-positive advanced and metastatic BC. Considering the success of this family of compounds in hormone-positive BC, new possible applications are being investigated in other molecular subtypes. This review summarizes the latest findings on the use of CDK4/6 inhibitors in HER2 positive BC.
CDK4/6 inhibitors in HER2-positive breast cancer / Corona, Silvia Paola; Ravelli, Andrea; Cretella, Daniele; Cappelletti, Maria Rosa; Zanotti, Laura; Dester, Martina; Gobbi, Angela; Petronini, Pier Giorgio; Generali, Daniele. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 112:(2017), pp. 208-214. [10.1016/j.critrevonc.2017.02.022]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2837605
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact